Tritanrix-HepB

BIOLOGICAL3 trials

Sponsors

GlaxoSmithKline

Conditions

Infections, StreptococcalStreptococcus Pneumoniae

Phase 3

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine

CompletedNCT00344318

GlaxoSmithKlineInfections, Streptococcal

Start: 2006-08-07End: 2007-10-17Updated: 2018-12-07

Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines

CompletedNCT00547248

GlaxoSmithKlineInfections, Streptococcal

Start: 2007-10-22End: 2008-10-07Updated: 2019-01-14

Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age

CompletedNCT00814710

GlaxoSmithKlineInfections, Streptococcal, Streptococcus Pneumoniae

Start: 2009-03-07End: 2009-11-13Updated: 2020-01-03

Related Papers

Randomized, Open-Label Study of the Impact of Age on Booster Responses to the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine in Children in India

Clinical and Vaccine Immunology2014-07-109 citations

The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.

2009-04-0167 citations